SCYNEXIS’s (SCYX) Overweight Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of SCYNEXIS (NASDAQ:SCYXFree Report) in a research note published on Monday, Benzinga reports.

Separately, StockNews.com cut shares of SCYNEXIS from a buy rating to a hold rating in a research note on Monday, March 18th.

Check Out Our Latest Report on SCYX

SCYNEXIS Stock Performance

NASDAQ SCYX opened at $1.80 on Monday. The firm’s fifty day moving average price is $1.69 and its two-hundred day moving average price is $1.86. The stock has a market cap of $67.95 million, a PE ratio of 1.36 and a beta of 1.57. SCYNEXIS has a fifty-two week low of $1.35 and a fifty-two week high of $3.87. The company has a debt-to-equity ratio of 0.13, a quick ratio of 6.88 and a current ratio of 7.66.

Institutional Investors Weigh In On SCYNEXIS

A number of institutional investors and hedge funds have recently made changes to their positions in SCYX. Citigroup Inc. bought a new position in SCYNEXIS in the 1st quarter worth approximately $26,000. State Street Corp lifted its holdings in shares of SCYNEXIS by 9.3% during the 1st quarter. State Street Corp now owns 78,630 shares of the company’s stock worth $307,000 after acquiring an additional 6,694 shares during the last quarter. Worth Venture Partners LLC lifted its holdings in shares of SCYNEXIS by 13.8% during the 1st quarter. Worth Venture Partners LLC now owns 560,517 shares of the company’s stock worth $2,192,000 after acquiring an additional 67,788 shares during the last quarter. Chicago Partners Investment Group LLC lifted its holdings in shares of SCYNEXIS by 20.4% during the 1st quarter. Chicago Partners Investment Group LLC now owns 50,192 shares of the company’s stock worth $106,000 after acquiring an additional 8,517 shares during the last quarter. Finally, Jane Street Group LLC bought a new stake in shares of SCYNEXIS during the 2nd quarter worth $48,000. Institutional investors and hedge funds own 54.37% of the company’s stock.

About SCYNEXIS

(Get Free Report)

SCYNEXIS, Inc, a biotechnology company, develops products for the treatment of fungal infections in the United States. It offers BREXAFEMME for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of various fungal infections, including invasive candidiasis, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.

Recommended Stories

Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.